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INTRODUCTION 
Organophosphate induced delayed polyneuropathy (OPIDP) is an 
uncommon clinical condition. It occurs in association with the ingestion of 
large amounts of organophosphate after the stimulation of cholinergic receptors 
(1). It is characterized by distal degeneration of some axons of both the 
peripheral and central nervous systems occurring one to four weeks after single 
or short-term exposures (2). The prevalence of OPIDP in patients with 
organophosphate poisoning is nearly 22% (3).  
 The clinical sequence can be of three types: Type I syndrome (acute 
poisoning) is characterized by acute cholinergic effects appearing within a day 
of exposure to opc, often within hours. Cholinergic symptoms include 
tachycardia or bradycardia, diarrhea, vomiting, fasciculations, sweating, 
salivation and micturition, which are treatable with atropine (4). Type II or 
Intermediate syndrome follows the intense cholinergic crises of 
organophosphate poisoning and occurs in up to 20 to 50% of cases depending 
on the severity of poisoning, its duration and the type of organophosphate 
compound. Their symptoms manifest 24 - 96 hrs after the poisoning on 
recovery from the cholinergic crises and include muscular weakness, affecting 
predominantly proximal limb muscles and neck flexors. Unlike the delayed 
polyneuropathy, this syndrome carries a death risk due to respiratory 
depression. The clinical course may last from 5 to 18 days (5). Type III 
syndrome (OPIDP) is induced by many organophosphate esters (ops), may 
cause a distal dying back axonopathy characterized by cramping muscle pain in 
the legs, paresthesia and motor shortcoming beginning 10 days to three weeks 
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after the initial exposure. Associated signs include high stepping gait associated 
with bilateral foot drop, absent ankle jerks, weakness of intrinsic hand muscles 
and wrist drop. Sensory symptoms may be present but it is predominantly a 
motor neuropathy. Pyramidal tract involvement may also present. Diagnosis is 
based on history of organophosphate poisoning, clinical findings, 
electromyography and nerve conduction studies which show typical 
denervation pattern. 
 Organophosphate induced delayed neuropathy (OPIDN) is a sensory-
motor distal axonopathy which usually occurs after the ingestion of large doses 
of certain organophosphate insecticides. Most of the patients developed a 
mixed polyneuropathy, mainly motor(6). The neurotoxic effects of 
organophosphates have been well known since the dramatic outbreak of 
"Ginger Jake Paralysis", which crippled as many as 50 000 in the USA in the 
1930's(7). Since then several other epidemics have occurred in different regions 
such as in Sri Lanka(8). In this epidemic area, adolescent Tamil girls attaining 
menarche or women right after childbirth were affected and developed 
polyneuropathy between fourteen and thirty days after gingili oil ingestion, 
following local customs and tradition. Recovery from OPIDN is considered to 
be generally poor. It is possible that several other factors such as the age of the 
patients, the difference in the chemical structure of the organophosphate and 
the duration of initial intoxication in some way contribute towards a favorable 
outcome(9). 
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REVIEW OF LITERATURE 
HISTORY: 
            In the era of industrial revolution many organophosphorous compounds 
were synthesized. Organophosphates (OPs) are chemical substances originally 
produced by the reaction of alcohols and phosphoric acid.  As early as 1854 
Clermont prepared tetra ethyl pyrophosphate (TEPP) OPC made its mark in 
modern chemistry when Lange and Krueger recorded the synthesis of di-
methyl di-ethyl phosphor fluoridates in 1932 (10). They observed that inhalation 
of these compounds produced blurring of vision and choking sensation. But 
OPC as pesticides were produced by a group of German scientists led by 
Gerhard Schrader, Farben Febriken and Bayer 1937. The possibilities of 
potential chemical warfare with these agents were explored by Nazis in World 
War II. Indeed Sarin (isopropyl methyl phosphonofluoridate) was used by Iraq 
against Kurdish rebels in villages of north IRAQ (11). The residues of Sarin 
were still found in analysis of the soil. In 1944 Schrader synthesized parathion 
which was widely used as a pesticide. In 1870 Fraser developed atropine as an 
antidote to physostigmine. Collomp in 1949 experimented atropine against 
muscarinic effects of nerve gas. In 1955 Davies introduced oximes and I.B 
Wilson confirmed its usefulness in acute opc poisoning. Namba for the first 
time used pralidoxime in his victims of opc poisoning in 1956. Lallement 
studied GK-11 an anti Glutamimetic drug as a neuro protective agent in OPC in 
1997. In 1998 adenosine receptor antagonist role was studied in OPC 
necessitating further studies.  
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Historic and new uses of organophosphates: 
 The first organophosphate was synthesized in 1850. Physostigmine was 
used to treat glaucoma in the 1870s. By the 1930s, synthetic cholinesterase 
inhibitors were being used for skeletal muscle and autonomic disorders. Some 
organophosphates were tried in the treatment of Parkinsonism. 
 In 1986, testing began for tacrine, the first cholinesterase inhibitor to be 
tried for Alzheimer disease; it was released for clinical use in 1993. The blood-
brain barrier has been the limiting factor in developing a cholinesterase 
inhibitor for use in dementia. A new drug, rivastigmine, is now available. 
Reported adverse effects are nausea and vomiting, with resultant weight loss 
because of the increase in cholinergic activity. It has been shown to be useful in 
mild to moderately severe Alzheimer disease. 
 Recently, pyridostigmine has been tried for the fatigue of post polio 
syndrome. Unfortunately, the study showed no benefit. 
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Table: 1: CLASSIFICATION AND THEIR STRUCTURE 
Sl. No. Common Name Trade Name 
1. Acephate  Asataf, Orthene, Starthene 
2. Chlorpyrifos Dursban, Durmet, Lorsban 
3. Dichlorvas Noovan 
4. Dimethoate Rogar, Tara 909, Fosfamid 
5. Fenitrothian Surmunion, Nitrophos  
6. Fenthion Baycid, Baytex 
7. Malathion Cythion, Chemathion 
8. Methyl Parathion Metacid, Folitav,  
9. Monocrotophos Monocron, Nuvacron, Luphos 
10. Phorate Thimet, Pempart 
11. Parathion  Folidol, Ekatox 
12. Phosphomidan Dimecron, Famfos 
13. Quinalphos  Ekalux 
 
GENERAL CHEMICAL STRUCTURE  
Organophosphorous compounds are basically esters of phosphoric acid 
or of   phosphorothioic acids (12).The R denotes either ethyl or methyl group. 
The organothiophosphates which contains double bonded sulphur group are 
converted into organophosphates in the liver. Phosphonate contains an alkyl(R-
) in place of one alkoxy group (RO-). The X is called the leaving group and is 
the principal metabolite for species identification. (13). 
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 RO  S (or O)  
   P 
   RO  X (Leaving Group) 
 
Table 2 
Highly toxic: 
Sl. no             Brand name          Chemical name 
1 Dimecron Phosphomidan 
2 Folidol Ethyl parathion 
3 Celethion Chlorthiophos 
4 Systox Demeton s methyl 
5 Trithion Carbophenothion 
6 Moonbug, metacid Methyl parathion 
7 Bloom Dichlorvas 
 
Moderately toxic: 
Sl. no Brand name Chemical name 
1 Baytex Fenthion 
2 Entex Formothion 
3 Finit Malathion 
4 Tic 20 Fenitrothion 
5 Spectacide Diazinon 
6 Canon, classic 20 Chlorpyriphos 
7 Abate Temephos  
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Others: 
Sl. no Brand name Chemical name 
1 Hydan, hinosan Edephenophos 
2 Kinadon, siccomedon Phosphenidone 
3 Josh, Shikari  Triazophos 
4 Monocrown, monosul Monocrotophos 
5 Rogor, Digor Dimethoate  
6 Ekalux Quinalphos 
7 Actellic  Pirimiphos 
 
KINETICS: 
 The kinetics of each group are highly dependent upon many factors such 
as route of administration such as ingestion, injection, inhalation, transdermal 
and transmucosal exposure, distance from target organs, local versus systemic 
metabolism and activation, route of elimination, endogenous hydrolysis and 
consumption of the compound by non specific esterases. Each group has its 
chemical structure, R- groups attached to the sulphur, carbon, or phosphorus 
entity, tightness of the bond to the central atom and the inherent affinity to 
cholinesterase. (14) After absorption the chemicals are equally distributed in all 
tissues but predominantly in liver and the renal. Lipophilic compounds reach 
maximum concentration in neural and other lipid rich tissues. Plasma half life 
after single dose administration depends upon the type of opc and route of 
exposure and it may range from few minutes to few hours. Metabolism occurs 
mainly by three ways namely oxidation, hydrolysis by esterases and transfer of 
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portion of molecule to glutathione. Urinary and faecal excretion occurs in 
48hours where in 80- 90% of the compound is eliminated (15).Most of the 
agents show some symptoms and signs within six to ten hours (16)  with the 
exception of fat soluble compounds where it may take several days  to weeks to 
manifest because the substance must be leached out of the fat. Some opc have 
to be activated to active toxic state (hepatic activation of parathion to 
paraxon).Studies reveal that these residues may remain for days to week even 
after treatment. (17) 
MECHANISM OF ACTION: 
Acetylcholine (ACh) is the neurotransmitter released at all 
postganglionic parasympathetic nerve endings and at the synapses of both 
sympathetic and parasympathetic ganglia. It is also released at the skeletal 
muscle myoneural junction, and serves as a neurotransmitter in the central 
nervous system. ACh is hydrolyzed by acetyl cholinesterase into two 
fragments: acetic acid and choline. 
Acetyl cholinesterase is present in two forms: True acetyl cholinesterase 
which is found primarily in the tissues and erythrocytes, and pseudo 
cholinesterase which is found in the serum and liver. 
Organophosphorous compounds are acid-transferring inhibitors of 
cholinesterase. They cause cholinesterase to become firmly (and sometimes 
irreversibly) phosphorylated. This means that the action of cholinesterase will 
be inhibited. Cleavage of the carbon-enzyme bond from ACh is complete in a 
few microseconds. However, the breaking of the phosphorus-enzyme bond 
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requires a period varying from 60 minutes to several weeks, depending on the 
organophosphorous compound involved. 
Reactivation of the inhibited enzyme may occur spontaneously. The rate 
of reactivation will depend on the species, the tissue, and the chemical group 
attached to the enzyme. Reactivation may be enhanced by hydrolysis of the 
acid-radical-enzyme through the use of oximes (i.e. reactivating agents).   
Response to reactivating agent is declining with time.  This process is being 
caused by "ageing" of the inhibited enzyme. Ageing is probably the result of 
the loss of one alkyl or alkoxy group, leaving a much more stable acetyl 
cholinesterase. The aged phosphorylated enzyme cannot be reactivated by 
oximes. 
Accumulation of acetylcholine causes over stimulation of both 
muscarinic and nicotinic receptors, and subsequently disrupts the transmission 
of nerve impulses in both the peripheral and central nervous system. (17) 
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Most of these OPC do not possess a positive charge; hence they react 
with esteratic site but not with anionic site. Splitting of the acid group then 
occurs.                                                        
The bond between phosphorous and esteratic site (free site) is more 
stable than the bond between carbon atom of acetyl choline and the same site. 
Thus blocking of the active site and consequent inactivation of enzymes results 
in accumulation of acetylcholine at cholinergic sites. Pseudo cholinesterase is a 
less specialized enzyme as it lacks an anionic site in a position that specially 
adapts it to react with acetylcholine. It does however react with acetyl choline, 
albeit, more slowly and also with a wide range of other esters  
BIOLOGICAL INTERACTIONS OF OPC (18): 
 
 
 
 
 
 
Fig.2 
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CLINICAL FEATURES 
 The clinical features depend upon the end points where sustained 
cholinergic stimulation takes place namely 
a. Post ganglionic parasympathetic hollow end organ (muscarinic) 
b. Sympathetic and parasympathetic ganglionic and somatic neuro 
muscular junction (nicotinic)    
c. Central nervous system affection (19) 
Following exposure to organophosphorous compounds, the toxic 
features are usually obvious within 30 minutes to 3 hours. This may be delayed 
in some cases depending on the rate and amount of systemic absorption. The 
majority of patients give a history of intentional or accidental ingestion of 
organophosphorous compounds. Toxicity is produced by the rapid absorption 
of the compound through the gastrointestinal, respiratory tracts and skin. 
The clinical symptoms and signs are non-specific and will depend on the 
specific agent, the quantity and the route of entry. Some patients present with 
vomiting, diarrhea and abdominal pain, whilst others may be unconscious on 
arrival at the hospital. A high index of suspicion is therefore needed to make an 
early diagnosis.   Early cases present predominantly with parasympathetic 
over-activity, and a characteristic garlic smell. The end result may be a multi-
system manifestation involving the gastrointestinal, respiratory, and 
cardiovascular and nervous systems, as well as involvement of skeletal muscle, 
other organs and metabolic effects such as hypo or hyperglycemia. Most 
fatalities occur within 24 hours and those who recover usually do so within 10 
days.  
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CARDIAC MANIFESTATIONS: 
The commonest cardiac manifestations following poisoning are 
hypotension (with warm, dilated peripheries), and bradycardia. Patients seldom 
present with tachycardia and hypertension due to predominant nicotinic 
receptor blockade. Cardiac manifestations are often the cause of serious 
complications and fatality. (20). 
Table 3. Symptoms and signs of organophosphorous poisoning 
Muscarinic receptors Nicotinic receptors Central receptors 
Cardiovascular 
• Bradycardia  
• Hypotension  
Respiratory 
• Rhinorrhoea  
• Bronchorrhoea  
• Bronchospasm  
• Cough  
Gastrointestinal 
• Nausea/vomiting 
• Increased 
salivation  
• Abdominal 
cramps  
• Diarrhea  
• Faecal 
incontinence  
Genitourinary 
• Urinary 
continence  
Eyes 
• Blurred vision  
• Increased 
Lacrimation  
• Miosis  
Glands 
• Excessive 
salivation  
Cardiovascular  
• Tachycardia  
• Hypertension  
Musculoskeletal  
• Weakness  
• Fasciculation  
• Cramps  
• Paralysis  
General effects  
• Anxiety  
• Restlessness  
• Ataxia  
• Convulsions  
• Insomnia  
• Dysarthria  
• Tremors  
• Coma  
• Absent reflexes  
• Respiratory 
depression  
• Circulatory 
collapse  
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The mechanism of cardiac toxicity is unclear and the following has been 
postulated: 
• A direct toxic effect on the myocardium  
• Over activity of cholinergic or nicotinic receptors causing hemodynamic 
alteration  
• Hypoxia  
• Acidosis  
• Electrolyte abnormalities  
• High dose atropine therapy (used as treatment for organophosphate 
poisoning).  
RESPIRATORY MANIFESTATIONS: 
Respiratory manifestations of acute organophosphorous poisoning 
include bronchorrhoea, rhinorrhoea, bronchospasm and laryngeal spasm. This 
is due to the action of the organophosphate on muscarinic receptors. The 
integrity of the airway may be compromised by excessive secretions. The 
nicotinic effects lead to weakness and subsequent paralysis of respiratory and 
oropharyngeal muscles. This increases the likelihood of both airway 
obstruction and aspiration of gastric contents. Finally, central neurological 
depression may lead to respiratory arrest.  
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GASTROINTESTINAL MANIFESTATIONS: 
Symptoms resembling gastroenteritis such as vomiting, diarrhea and 
abdominal cramps are the first to occur after oral ingestion of an 
organophosphorous compound.  
NEUROLOGICAL MANIFESTATIONS: 
A large number of patients, following acute exposure to 
organophosphorous compounds, require prolonged ventilatory support in the 
intensive care unit due to neuromuscular weakness. The neurological 
manifestations have therefore been a primary focus of interest. There has been 
an emphasis on reducing the incidence of neuro-muscular respiratory failure. 
Three different types of paralysis are recognized based largely on the time of 
occurrence and their differing pathophysiology: 
• Type I paralysis or acute paralysis  
• Type II paralysis or Intermediate syndrome  
• Type III paralysis or Organophosphate- induced delayed polyneuropathy  
Type I paralysis:  
  Acute paralysis is seen during the initial cholinergic phase. This 
is when large numbers of both muscarinic and nicotinic receptors are occupied 
by acetylcholine, leading to persistent depolarization at the neuromuscular 
junction. Clinical features include muscle fasciculation, cramps, twitching and 
weakness. At this stage the patient may require ventilatory support due to the 
weakness of the respiratory muscles leading to respiratory depression and 
arrest. 
 15
Type II paralysis or Intermediate syndrome:  
This was first described in 1974 by Wadia et al (20) as type II paralysis 
and subsequently termed "The Intermediate Syndrome" by Senanayake. This 
syndrome develops 24-96 hours after the poisoning. Following recovery from 
the acute cholinergic crisis, and before the expected onset of delayed 
neuropathy, some patients develop a state of muscle paralysis.  
 The cardinal feature of the syndrome is muscle weakness affecting the 
proximal limb muscles and neck flexors. There is a relative sparing of the distal 
muscle group. One of the earliest manifestations in these patients is the 
inability to lift their head from the pillow (due to a marked weakness in neck 
flexion). This is a useful test to establish whether or not a patient is likely to 
develop respiratory muscle weakness. Of the cranial nerves, those supplying 
the extra-ocular muscles are mostly involved, with a lesser effect on VII and X. 
This syndrome persists for about 4-18 days and most patients will survive 
unless infection or cardiac arrhythmias complicate the course. 
Type III paralysis or organophosphate- induced delayed polyneuropathy 
(OPIDP): 
Organophosphate-induced delayed polyneuropathy (OPIDP) is a rare 
toxicity resulting from exposure to certain organophosphorus (OP) esters. It is 
characterized by distal degeneration of some axons of both the peripheral and 
central nervous systems occurring 1-4 weeks after single or short-term 
exposures.  
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Cramping muscle pain in the lower limbs, distal numbness and 
paraesthesiae occur, followed by progressive weakness, depression of deep 
tendon reflexes in the lower limbs and, in severe cases, in the upper limbs. 
Signs include high-stepping gait associated with bilateral foot drop and, in 
severe cases, quadriplegia with foot and wrist drop as well as pyramidal signs. 
In time, there might be significant recovery of the peripheral nerve function 
but, depending on the degree of pyramidal involvement, spastic ataxia may be a 
permanent outcome of severe OPIDP. Human and experimental data indicate 
that recovery is usually complete in the young.  
At onset, the electrophysiological changes include reduced amplitude of 
the compound muscle action potential, increased distal latencies and normal or 
slightly reduced nerve conduction velocities. The progression of the disease, 
usually over a few days, may lead to non-excitability of the nerve with 
electromyographical signs of denervation. Nerve biopsies have been performed 
in a few cases and showed axonal degeneration with secondary demyelination. 
Neuropathy target esterase (NTE) is thought to be the target of OPIDP 
initiation. The ratio of inhibitory powers for acetyl cholinesterase and NTE 
represents the crucial guideline for the etiological attribution of OP-induced 
peripheral neuropathy. In fact, pre-marketing toxicity testing in animals selects 
OP insecticides with cholinergic toxicity potential much higher than that to 
result in OPIDP. Therefore, OPIDP may develop only after very large 
exposures to insecticides, causing severe cholinergic toxicity. However, this 
was not the case with certain triaryl phosphates that were not used as 
insecticides but as hydraulic fluids, lubricants and plasticisers and do not result 
in cholinergic toxicity. Several thousand cases of OPIDP as a result of 
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exposure to tri-ortho-cresyl phosphate have been reported, whereas the number 
of cases of OPIDP as a result of OP insecticide poisoning is much lower. 
Finally, several observational studies on long-term, low-level exposures to 
OPCs that sometimes reported mild, inconsistent and unexplained changes of 
unclear significance in peripheral nerves are briefly discussed. 
OTHER EFFECTS OF OPC MAY INCLUDE 
• Neuropsychiatric effects: Impaired memory, confusion, irritability, 
lethargy, psychosis, and chronic organophosphate-induced 
Neuropsychiatric disorders have been reported. The mechanism is not 
proven.(21) 
• Extra pyramidal effects: These are characterized by dystonia, cogwheel 
rigidity, and parkinsonian features (basal ganglia impairment after 
recovery from acute toxicity). 
• Other neurological and/or psychological effects: Guillain-Barré–like 
syndrome and isolated bilateral recurrent laryngeal nerve palsy are 
possible.(22) 
• Ophthalmic effects: Optic neuropathy, retinal degeneration, defective 
vertical smooth pursuit, myopia, and miosis (due to direct ocular 
exposure to organophosphates) are possible. 
• Ears: Ototoxicity is also possible(23). 
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MODIFIED DREISBACH’ CLINICAL CRITERIA – KARNIT (24) 
 GRADE I   -  Mild symptoms related to portal of entry. 
    Nausea, vomiting in case of ingestion  
Cough, burning sensation in the chest in case of 
inhalation Mild systemic symptoms like headache, 
dizziness, weakness  
 GRADE II - Moderate systemic intoxication  
    Abdominal pain and diarrhea in case of ingestion. 
Tightness in chest, difficulty in breathing in case of 
inhalation 
Salivation, Lacrimation, sweating, papillary 
changes. Bradycardia, confusion, tremor, 
restlessness. 
 GRADE III - Severe systemic intoxication  
    Respiratory depression, generalized weakness  
    Cyanosis, peripheral circulatory failure,  
Convulsion, coma. 
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DIAGNOSTIC CRITERIA (19) 
• INVESTIGATORY MODALITES: ESTIMATION OF 
CHOLINEESTERASE LEVELS:  Organophosphate (OP) toxicity is a 
clinical diagnosis. Confirmation of organophosphate poisoning is based 
on the measurement of cholinesterase activity; typically, these results 
are not readily available. Although RBC and plasma (pseudo) 
cholinesterase levels can both be used, RBC cholinesterase correlates 
better with CNS acetyl cholinesterase (AChE) and is, therefore, a more 
useful marker of organophosphate poisoning. 
o  Measurement of RBC and plasma cholinesterase levels prior to 
treatment with pralidoxime (2-PAM). Monitoring serial levels 
can be used to determine a response to therapy. 
o RBC AChE represents the AChE found on RBC membranes, 
similar to that found in neuronal tissue. Therefore, measurement 
more accurately reflects nervous system OP AChE inhibition. 
o Plasma cholinesterase is a liver acute-phase protein that circulates 
in the blood plasma. It is found in CNS white matter, the 
pancreas, and the heart. It can be affected by many factors, 
including pregnancy, infection, and medical illness. Additionally, 
a patient's levels can vary up to 50% with repeated testing. 
o RBC cholinesterase is the more accurate of the 2 measurements, 
but plasma cholinesterase is easier to assay and is more readily 
available. 
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• Cholinesterase levels do not always correlate with severity of clinical 
illness. 
• The level of cholinesterase activity is relative and is based on population 
estimates. Neonates and infants have baseline levels that are lower than 
adults. Because most patients do not know their baseline level, the 
diagnosis can be confirmed by observing a progressive increase in the 
cholinesterase value until the values plateau over time. 
• Falsely depressed levels of erythrocyte cholinesterase can be found in 
pernicious anemia, hemoglobinopathies, use of antimalarial drugs, and 
oxalate blood tubes. 
• Falsely depressed levels of plasma cholinesterase are observed in liver 
dysfunction, low-protein conditions, neoplasia, hypersensitivity 
reactions, use of certain drugs (succinylcholine, codeine, and morphine), 
pregnancy, and genetic deficiencies. 
• Other laboratory findings include leukocytosis, hemoconcentration, 
metabolic acidosis, hyperglycemia, hypokalemia, and hypomagnesemia. 
IMAGING STUDIES:  
A chest radiograph may reveal pulmonary edema but typically adds little 
to the clinical management of a poisoned patient. Electrocardiographic 
manifestations include prolonged Q-Tc intervals, elevation of the ST segment, 
inverted T waves and a prolonged PR interval. There may also be rhythm 
abnormalities such as sinus bradycardia, ventricular extra-systoles, ventricular 
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tachycardia and fibrillation. Ludomirsky et al described three phases of cardiac 
toxicity following organophosphate poisoning: 
• Phase I: A brief period of increased sympathetic tone  
• Phase II: A prolonged period of parasympathetic activity including AV 
node blockade  
• Phase III: Q-T prolongation followed by torsades de pointes, 
ventricular tachycardia and ventricular fibrillation (25) 
THERAPEUTIC CONSIDERATIONS 
 Medical Care: Airway control and adequate oxygenation are paramount 
in organophosphate poisonings. Intubations may be necessary in cases of 
respiratory distress due to laryngospasm, bronchospasm, bronchorrhoea, or 
seizures. Immediate aggressive use of atropine may eliminate the need for 
intubation. (26) Succinylcholine should be avoided because it is degraded by 
acetyl cholinesterase (AChE) and may result in prolonged paralysis. 
• Continuous cardiac monitoring and pulse oximetry should be 
established; an ECG should be performed. Torsades de Pointes should 
be treated in the standard manner. The use of intravenous magnesium 
sulfate has been reported as beneficial for organophosphate toxicity.(27) 
The mechanism of action may involve acetylcholine antagonism or 
ventricular membrane stabilization. 
• Remove all clothing and gently cleanse patients suspected of 
organophosphate exposure with soap and water because 
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organophosphates are hydrolyzed readily in aqueous solutions with a 
high pH. Consider clothing hazardous waste and discard accordingly. 
• Health care providers must avoid contaminating themselves while 
handling patients. Use personal protective equipment, such as neoprene 
or nitrile gloves and gowns, when decontaminating patients because 
hydrocarbons can penetrate non polar substances such as latex and vinyl. 
Use charcoal cartridge masks for respiratory protection when 
decontaminating patients who are significantly contaminated. 
• Irrigate the eyes of patients who have ocular exposure using isotonic 
saline. 
• If ingestion occurred within 30 to 60minutes placement of nasogastric 
tube and administration of activated charcoal in a dose, 1g/kg orally. 
Cathartics are contraindicated because of electrolyte imbalance. (28)   
 Atropine administration: 3-5mg rapid intravenous should be given to 
reach effective atropinisation. The adequate atropinisation is gauged by five 
parameters. 
 1. Pulse rate >85/min 
 2. Systolic blood pressure >80mmHg 
 3. Absence of lung crackles 
 4. Dry axilla 
 5. No constricted pupils (20) 
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Then after three to five minutes, if the parameters are not attained 
double the initial dosing. Atropine should be given in doubling dose pattern till 
adequate atropinisation. 
 Maintenance of atropinisation: 10- 20% of the bolus dose should be 
given as infusion in 100ml normal saline and the parameters are assessed every 
15minutes. If there is inadequate atropinisation superimposed bolus in the 
dosage of 3-5mg should be given. Atropine should be tailored down hourly for 
six hours and then every two to three hours for the next 24hrs. Meticulous 
watch for atropine toxicity such as agitation, confusion, retention of bladder, 
hyperthermia, ileus and tachycardia should be done.    
 Glycopyrrolate can be used instead of atropine. It does not raise the 
heart rate  (56). 
OXIMES: PRALIDOXIME (2-PAM OR PROTO PAM) (29) 
Cholinesterase reactivation 
Oximes are nucleophilic agents that re-activate the phosphorylated 
acetyl cholinesterase by binding to the organophosphorous molecule. The use 
of oximes in acute organophosphorous poisoning has been a controversial 
subject for the last two decades as there have been very few randomized 
controlled trials that have addressed the role of pralidoxime (PAM). 
Pralidoxime has three main actions 
• A direct reaction converting the organophosphate to a harmless 
compound.  
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• A transient reaction protecting the enzyme from further inhibition.  
• Reactivation of the inhibited alkyl phosphorylated enzyme to free the 
active unit (if given early enough)  
The reactivating action of pralidoxime is most marked at the nicotinic 
skeletal neuromuscular junction. It does not reverse the muscarinic 
manifestations of organophosphorous poisoning. Pralidoxime should be started 
as early as possible to prevent permanent binding of the organophosphate to 
acetyl cholinesterase. Once this has occurred, receptor regeneration is required 
to allow recovery. The recommended dose of pralidoxime in 
organophosphorous poisoning is 500 mg/hr infusion for the first 48 hrs 
followed by 1 gm iv tds for another 3 days. Pralidoxime should be continued 
until adequate spontaneous ventilation is achieved by the patient. The effective 
plasma concentration is 4mg/litre and the patient should show signs of 
improvement 10- 40 minutes after its administration. Plasma and pseudo 
cholinesterase levels should ideally be monitored during treatment. Side effects 
of pralidoxime include drowsiness, visual disturbances, nausea, tachycardia 
and muscle weakness, so treatment should be reserved for potentially fatal 
cases. Fresh frozen plasma can also be used in the management of OPC (57). 
There is no proven effective treatment for OPIDP till now. So prevention is 
only way. 
PREVENTION AND EDUCATION 
Improved regulation of the availability of pesticides, strict regulation of 
vendors, and modifications in packaging of pesticides may all help reduce the 
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use of organophosphates as poisons. Adequate provision of information to the 
public, regular training of health care providers, better availability of drugs / 
antidotes and the establishment of poison information centers will facilitate in 
reducing the morbidity and mortality related to organophosphorous poisoning. 
Insecticides should be kept out of reach of children, to prevent accidental 
poisoning. During agricultural spraying, proper precautions should be taken to 
prevent inhalation and accidental ingestion of the substance. The greatest 
incidence of organophosphorous poisoning was reported from Japan where 
there were 19,436 cases over a period of 17 years (1953-1969).WHO used data 
from 19 countries and reported approximately 5,00,000 cases of pesticide 
poisoning annually. Of these 99% belong to third world countries (29).In1981 
the estimate was 75,000 cases annually and rose to 3million in 1983 and 
majority were under the age of 30 (30). Pesticide poisoning contributes more 
than forty percent of cases in Poison Centre GGH Chennai. The mortality rate 
due to this poison is 42.29% (case register2001-2004). The victims are farmers 
of rural South India.  
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OBJECTIVES 
1. To describe the epidemiology of organophosphorous poisoning in 
poison centre, Government General Hospital, Chennai. 
2. To study the clinical profile of organophosphorous poisoning in poison 
centre, Government General Hospital, Chennai                                                                  
3. To analyze the epidemiological and clinical factors in correlation to 
severity and outcome of organophosphorous poisoning in poison centre, 
Government General Hospital, Chennai. 
4. To analyze the incidence of organophosphate induced delayed 
polyneuropathy in the patients admitted with OPC poisoning in poison 
centre, Government General Hospital, Chennai. 
5 To study the correlation between the incidence of delayed 
polyneuropathy and the compound consumed, quantity, duration of 
hospital stay and ventilatory support.  
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MATERIALS AND METHOD 
SETTING:  
  This study was conducted in the Poison control, training and research 
centre, GGH, Chennai in collaboration of Institute of Internal Medicine, 
Institute of Biochemistry and Institute of Neurology. It was a prospective study 
done during the period from September2007- September2008. 29 patients with 
history and clinical features suggestive of organophosphorous poisoning were 
selected irrespective of age and sex.  
EXCLUSION CRITERIA 
1. Patients with other pesticide poisoning were excluded (eg. Carbamate, 
organochlorous compounds) by clinical features and confirmed by thin 
layer chromatographic analysis of gastric aspirate. 
2. Patients with other poisoning such as oleander, oduvanthazai, and drug 
over dosage (nicotine replacements, inocybe, clitocybe, pilocarpine, 
opioids, phenothiazines, bethanechol etc) known to mimic the clinical 
picture of organophosphorous poisoning were excluded. 
3. Patients with known medical illness such as neuromuscular disorders 
like myasthenia gravis or muscular dystrophy, hypokalemic periodic 
paralysis and conditions known to alter biochemical parameters were 
excluded. 
 Patients with known history of exposure to organophosphorous 
compounds were taken into consideration. The reliability on exposure was 
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reinforced by definite history from the patients and their attendants. The 
container from which the poison where consumed were studied for the type and 
the quantity estimated. Each patient registered for the study went through 
detailed clinical evaluation as per the proforma. The cases were divided into 
three groups as mild, moderate and severe by modified DREISBACH criteria. 
All patients underwent baseline laboratory investigations. The gastric aspirate 
was analyzed by thin layer chromatography method for the detection of poison. 
 All patients underwent complete Hemogram, renal function test, liver 
function test, ECG, chest roentgenogram, ultra sonogram of the abdomen and 
nerve conduction studies.  
 Serum AChE was measured on day 1, 2 and 3.  
  The other biochemical markers such as liver enzymes and amylase were 
taken on day1. 
BI0CHEMICAL MARKERS AND THE METHODS EMPLOYED- 
(KITS) 
1. CHOLINESTERASE - KINETIC COLORIMETRIC 
METHOD (31) 
2. SGOT (AST)   - UV KINETIC METHOD (32) 
3. SGPT                                       - (MODIFIED IFCC METHOD) (33) 
4. ALKALINE PHOSPHATASE  - PNPP METHOD (34) 
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5. ALBUMIN                           - BCG METHOD(35) 
6. CK                                        - UV KINETIC METHOD (36) 
7. AMYLASE                            - CNP – G3 METHOD (37) 
8. LDH                                        - UV KINETIC METHOD (33) 
Ventilatory support was considered in patients with following 
parameters   
a. RR >35/min  
b. Apnea or obvious hypoventilation 
 c. Persistent cyanosis, excessive secretions, depressed level of 
consciousness, inability to protect the air way (34) 
d. PaO2          < 60 mmHg, FiO2 >0.6 
 PaCO2         > 50 mmHg, pH     <7.2 
 Mechanical ventilation was performed with assist control mode and 
SIMV either as volume or pressure control. Positive end expiratory pressure 
was titrated to keep SaO2 above 94% with 40% FIO2. Weaning was performed 
using either T-tube trials or pressure support weaning. All patients were 
monitored meticulously and vital signs assessed till the outcome.   
Detailed evaluation of each patient was made. Each variable in the pro-
forma was correlated with severity and mortality.  
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RESULTS 
Epidemiological Pattern of OPC in Poison Centre, Govt. General Hospital 
Table: 4 - Age Distribution 
Sl.No. Age Group in years Frequency(n) Percentage 
1. < 20 3 10.4 
2. 21-30 12 41.4 
3. 31-40 5 17.2 
4. > 40 9 31.0 
 Total 29 100.00 
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Fig: 3 - Age Distribution 
 Majority of the patients were in the 21 to 30 age group. The number of 
people between the age group 20 to 40 accounts for 59%.  
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Table: 5 – Age Distribution and Outcome 
Sl.No. Age Group in years Death Percentage 
1. <= 20 1 3.4 
2. 21-30 1 3.4 
3. 31-40 0 0.0 
4. > 40 3 10.3 
 Total 5 100.00 
 
Three people in the age group of above forty died. The percentage is 10.3% 
     
 
 
 
 
 
Fig: 4 – Age Distribution and Outcome 
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Table 6 Sex Distribution 
Sl.No. Sex Frequency(n) Percentage 
1. Male  24 82.8 
2. Female  5 17.2 
 
Frequency(n)
83%
17%
1 Male 
2 Female 
 
Fig: 5- Sex Distribution 
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Incidence of OPC was more in males when compared to females in our 
series. 24 out of 29 patients are males. 
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Table 7 - Occupation 
Sl.No. Occupation Frequency(n) Percentage Expired 
1. Agriculture 8 27.6 1 
2. Unskilled Labour 13 44.8 2 
3. Others  8 27.6 2 
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Fig: 6- occupation 
 More than 40 percent of the cases of OP poisoning were unskilled 
labors. Farmers made up 25%. 
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Locality: 
Distance from the Poison Centre, Govt.General Hospital in Kilo Meters. 
Table 8 – Locality  
Sl.No. Locality (kms) Frequency(n) Percentage 
1. <= 100            12 41.4 
2. > 100             17 58.6 
 
Table 9 - Type of Poison consumed 
Sl.No. Type of Poison consumed  Frequency(n) Percentage 
1. CHLORPYRIFOS 2 6.8   
2. PHOSPHOMIDAN 2 6.8 
3. QUINALPHOS          4 13.8 
4. TRIAZOPHOS       1 3.4 
5. METHYL PARATHION  2 6.8 
6. MONOCROTOPHOS 10 34.4 
7. DIMETHOATE 6 20.6 
8. PIRIMIPHOS 1 3.4 
9. MECRON 1 3.4 
 Total  29 100.00 
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Fig: 7- Type of poison consumed 
Most of the patients in this series consumed Monocrotophos (n=10) and 
Dimethoate (n=6).  Four patients consumed Quinalphos. 
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Table.10- Route of Exposure 
Sl.No. Route of Exposure Frequency(n) Percentage 
1. Ingestional 27 93.2 
2. Inhalational 1 3.4 
3. Topical 1 3.4 
 
Frequency(n)
1 Ingestional
2 Inhalational
3 Topical
 
Fig: 8- Route of exposure 
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 Ingestional exposure was more common among in the series (93.2%) 
and all of the patients in this entity fell under the severe grade of Dreisbach’s 
criteria  
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Table 11: Intention of Poison: 
SL. No: Intention frequency percentage 
1 Suicidal 28 96.6 
2 Accidental 1 3.4 
 
In this series 28 patients consumed OPC with suicidal intention. [96.6%]  
 
Table.12 Duration of stay in hospitals 
Sl.No. Duration of Stay in 
Hospitals (in days) 
Frequency(n) Percentage 
1.       <= 5                    7 24.1 
2. 6-10 10 34.5 
3. > 10 12 41.4 
  29 100.00 
 
 The mean duration of stay in the hospital is 7.25 days (SD 4.64)   
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Table 13 :Quantum of exposure 
Sl.No. Quantity consumed (ml.) Frequency (n) Percentage 
1. NA 3 10.3 
2. <=50 4 13.9 
3. 51-100 13 44.9 
4. >100 9 30.9 
 Total 29 100.00 
 
The non availability of data in 3 patients was due to two reasons.  
1. Two cases had inhalational and topical forms of exposure so the 
quantity cannot be ascertained  
2. Patient did not know the quantity of consumption 
The average quantity of consumption in this series amounts to 101.58ml.  
PERIOD INTERVAL FOR INITIATION OF TREATMENT  
a) Initiation of First Aid (Gastric Lavage/activated charcoal) 
Table 14: Initiation of First Aid 
Sl.No. Initiation of First aid 
(Hours.) 
Frequency (n) Percentage 
1. <=1 21 72.4 
2. 1-2 6 20.7 
3. >2 2 6.9 
 Total 29 100.00 
 
 Out of 29 patients 27 received first aid in a medical facility within two 
hours.  
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LABORATORY PARAMETERS:  
1. Average hemoglobin observed in this series – 12.7 g/dl (SD =1.66)  
2. Total WBC count had a range between 4800 and 23600 cells per cubic 
mm. and it had a mean value 8686 (S.D-3433) 
3.  Routine Bio-chemistry 
Table 15: Bio Chemistry Values 
Sl.No. Values Mean S.D. (+/-) 
1. Blood Sugar mg/dl. 104.5 33.96 
2. Urea mg/dl. 30.7 9.4 
3. Creatinine 0.83 0.18 
4. Sodium 134 6.3 
5. Potassium 3.83 0.55 
 
4. Liver Function Test: These parameters did not have any correlation with 
severity or outcome. The values of 29 patients are given below: 
Table 16: LFT 
Sl.No. Values Mean S.D. (+/-) 
1. SGOT  IU/L 37.05 16.8 
2. SGPT  IU/L 32.0 10.0 
3. Total Protein g/dl 6.51 0.50 
4. Albumin  g/dl 3.70 0.78 
5. SAP IU/L 96.1 28.2 
6. Bilirubin  0.76 0.11 
7. Amylase  101 30.7 
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Pseudo cholinesterase Levels in OPC poisoned Patients 
Table 17: Pseudo cholinesterase Levels in OPC poisoned Patients 
Serum ChE 
Level IU/L 
N Mean SD Minimum 
Value 
Maximum 
Value 
Range 
Day 1 29 706.3 833.8 134 4317 4183 
Day 2 29 833.8 892.9 141 4585 4444 
Day 3 27 1321.1 1012.1 148 3216 3068 
  
 In this series, sequential post exposure estimations of the ChEs up to 3 
days revealed significant rise in the values correlated with substantial clinical 
improvement. 
Mean
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SERUM AMYLASE   
 In all 29cases, serum amylase and ultra sonogram of the abdomen were 
done. Sonography of the abdomen was normal in all cases.  The mean serum 
amylase level in the series 101 U/L. (SD – 30.7)  
Pseudo cholinesterase Levels in OPC poisoned Patients 
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VENTILATORY SUPPORT 
Out of 29 patients 21 needed ventilatory support (72.4%). All patients 
were initiated on assist control mode. 
 The average duration of mechanical ventilation in the series was 9.2days 
(S.D=6.56). 5 out of 21 cases on mechanical ventilation expired .The morality 
rate among patients on mechanical ventilation was 23.8%. The mortality rate 
differed with patients with ventilatory support and with that of no support 
(0.0%).   
Table 18 - Ventilatory Support & Outcome 
 Ventilatory Support No Support 
No. of Patients  21 8 
Recovered  16 8 
Expired  5 0 
  
Ten cases needed Tracheostomy during mechanical ventilation (34.5%) 
Nerve conduction studies: 
24 patients underwent nerve conduction studies in the third or fourth 
week of hospital stay according to the clinical severity. In the nerve conduction 
study, compound muscle action potential, sensory nerve action potential and 
nerve conduction velocities were measured in all four limbs. The normal values 
of these parameters were taken as controls.  Thirteen patients had evidence of 
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OPIDP. Three patients had evidence of significant axonopathy, 6 patients had 
evidence of demyelination and 8 patients had evidence of sensory neuropathy. 
One patient had evidence of axonopathy, demyelination and sensory 
neuropathy and two patients had evidence of axonopathy and sensory 
neuropathy. One patient had evidence of demyelination and sensory 
neuropathy. Five patients had evidence of demyelination alone and four 
patients had evidence of sensory neuropathy alone. All Patients with 
axonopathy also had evidence of either demyelination or sensory neuropathy or 
both.  
Table 19:  Nerve conduction abnormalities: 
Sl. 
No. 
Type of Poison 
Consumed 
Frequency 
(n) Death Axonopathy  Demyelination  
Sensory 
neuropathy 
1 Chlorpyrifos 2 0 0 0 1 
2 Phosphomidan 2 1 0 0 0 
3 Quinalphos          4 0 0 1 0 
4 Triazophos       1 0 0 0 0 
5 Methyl parathion  2 0 0 1 0 
6 Monocrotophos 10 3 1 4 3 
7 Dimethoate 6 1 2 1 1 
8 Pirimiphos 1 0 0 0 1 
9 Mecron 1 0 0 0 0 
  Total 29 5 3 7 6 
 
 43
0
2
4
6
8
10
12
C
H
LO
R
P
Y
R
IF
O
S
P
H
O
S
P
H
O
M
ID
A
N
Q
U
IN
A
LP
H
O
S
   
   
   
TR
IA
ZO
P
H
O
S
   
   
M
E
TH
Y
L
P
A
R
A
TH
IO
N
 
M
O
N
O
C
R
O
TO
P
H
O
S
D
IM
E
TH
O
A
TE
P
IR
IM
IP
H
O
S
M
E
C
R
O
N
1 2 3 4 5 6 7 8 9
sensory neuropathy
demyelination 
axonopathy  
Frequency(n)
 
Fig: 9- Nerve conduction abnormalities 
Outcome   
In this series 5 patients expired. The mortality rate was 17.2%. In all 
cases primary cause of death was respiratory failure with secondary cardiac 
arrest. It has resulted from central respiratory depression, respiratory muscle 
weakness, increased bronchial secretions, bronchospasm and acute pulmonary 
oedema. All cases needed ventilatory support. 
Out of these five deaths, three was due to ingestion of Monocrotophos. 
One was due to Dimethoate and the other was due to Phosphomidan. 
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Fig: 10- Outcome 
Table 20:  Agents causing death 
Sl.No. 
Type of Poison 
consumed 
Frequency 
(n) Percentage Death 
1 CHLORPYRIFOS 2 6.8 0 
2 PHOSPHOMIDAN 2 6.8 1 
3 QUINALPHOS          4 13.8 0 
4 TRIAZOPHOS       1 3.4 0 
5 METHYL PARATHION  2 6.8 0 
6 MONOCROTOPHOS 10 34.4 3 
7 DIMETHOATE 6 20.6 1 
8 PIRIMIPHOS 1 3.4 0 
9 MECRON 1 3.4 0 
 Total 29 100 5 
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In this series ten patients were admitted after consuming 
Monocrotophos. Out of these ten patients, three were expired. In the remaining 
seven one developed axonopathy, four patients developed demyelination and 
two patients developed sensory neuropathy. 
In this series six patients were admitted with Dimethoate ingestion. One 
patient was expired. In the remaining five, two patients developed axonopathy. 
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DISCUSSION 
 Comprehensive analysis of 29 cases of acute organophosphorous 
poisoning. 
EPIDEMIOLOGY OF ORGANOPHOSPHOROUS POISONING:  
Age pattern: 
In this series 15 cases were below the age of 30.WHO has reported 
about 3million cases of opc exposure and 40,000 deaths annually  and majority 
were under the age group of thirty. (30) Murat Sungur and Muhammed Güven et 
al of turkey observed the mean age group of opc exposure was 30±15 years.(18) 
Karalliedde L, Senanayake N.et al of SRILANKA documented 91% of their 
cases were under the age of 30.(40). In Kashmir valley Malik et al. revealed that 
33.5% of the cases of opc were under the age of 25. (41) In Mangalore, 
Karnataka, India the most common age group to be affected was 20-30 tears 
(36.6%)  (30). The series reported in this thesis   had the similar pattern of age 
group affection. The reason could be that this age group, by all probability, is 
vulnerable to various emotional conflicts that occur during this phase of life. 
This young age group affected by exposure form the viable entity of any 
population both in terms of procurement and productivity. This case study and 
the case reports mentioned above throw light on the target age group for 
educative and preventive programmes to reduce the incidence of opc 
poisoning.       
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SEX DISTRIBUTION  
 In poison centre GGH Chennai males were exposed more when 
compared to female population.(82.8% versus 17.2%). On the contrary to the 
series in Murat Sungur study of 47 cases of opc in Turkey (18) [(female n=25, 
male=22)] and. Malik et al.  Observation of 122 cases in Kashmir valley 
[(female n=114, male=50)] female intoxication was more (41). In Srilanka and 
Mangalore had similar pattern to the case series of the poison centre.(male 
86%-female 14%).S.Shivakumar and K.Raghavan et al of Tamilnadu reported 
165 cases of  organophosphorous poisoning and sex distribution was similar to 
the case series (male n=122, female n=45)(38).This variation was due to 
handling of poison by the respective sex in their respective locality. In Kashmir 
the female populations are predominantly employed in apple orchards and they 
are involved in pesticide control. In southern part of India males are actively 
involved in spraying fertilizers and pesticides. 
OCCUPATION AND SOCIOECONOMIC STATUS  
Wesselling C, McConnell R, Partanen T, Hogstedt C et al reported that 
large worker populations in the Third World were exposed to increasing 
amounts of pesticides, including pesticides severely restricted and banned in 
industrialized countries. Studies on knowledge, attitudes, and practices indicate 
that unsafe use of pesticides was the rule in Third World countries (43).In our 
case series 21 out of 29 cases were agriculturists and unskilled labourers. In 
Kashmir valley, two third of the population who had exposure were engaged in 
apple orchard. In Karnataka, agriculturists formed the majority. Students 
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formed the predominant group in Nepal (44) whereas in Almeria exposure was 
more in green house workers (45). 
INTENTION OF POISON: 
Estimates from the WHO indicate that each year, 1 million accidental 
poisonings and 2 million suicide attempts involving pesticides were happen 
worldwide (46). In the series majority of cases were suicidal in nature which was 
consistent with other workers. 28 cases (96.6%) were suicidal and 1 case 
(3.4%) had accidental exposure. 
Murat Sungur and Muhammed Güven et al observed 68%of opc 
poisoning reported was of suicidal exposure and Karalliedde L, Senanayake N 
et al of SRILANKA had similar pattern. Malik et al. reported 74.4% of cases 
were of suicidal in nature and rest (25.6%) had accidental exposure. Palimar 
Vikram MD, Arun M MD, DNB et al in their case study of 153 cases in 
Mangalore reported 98.7%of suicidal exposure. Most of the agriculturists 
consume for the fact of failure of crops, increasing debts coupled with the easy 
availability of poison. 
 2700 people are referred to hospital for self poisoning each week in the 
United Kingdom alone (47). It is likely to be even more difficult for the 
developing world, with its limited resources, to address this problem 
effectively. However, we think that the time has come to acknowledge the 
seriousness of the situation as a first step towards preventing this massive 
unnecessary loss of life. 
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ROUTE OF EXPOSURE: 
Ingestion of the OPC poisoning (n=27) formed the majority in this series 
apart of inhalational (n=1) and topical (n=1) form of exposure. Arup Kumar 
Kundu, JD Mukhopadhyay, AK Saha, S Das et al (48)studied 108 patients in sub 
urban West bengal poison.90 consumed the poison and the death rate was12% 
and it had positive correlation with outcome. In Kashmir Valley out of 164 
cases-ingestional route (n=140), inhalational (n=7) and topical exposure 
(n=17). In the Turkey study the gastrointestinal route was the main route in 44 
(93.6%) patients. 
TYPE OF POISON 
 In this study Monocrotophos (n=10 34.4%), Dimethoate (n=6 20.6) and 
Quinalphos (n-4 13.8%) were the most common type of poison consumed 
when compared to other workers.  
 Monocrotophos was consumed by ten patients. In these three were 
expired. In the remaining seven, one developed axonopathy, four developed 
demyelination and two developed sensory neuropathy. 
Six patients were admitted with Dimethoate ingestion. One patient was 
expired. In the remaining five, two patients developed axonopathy. 
 Murat Sungurb et al in turkey observed the three common type of opc 
were:  
Agent Number of patients
Dichlorvas 24 (51.1%) 
Ethyl-Parathion 5 (10.6%) 
Fenthion 4 (8.5% 
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In sub urban West Bengal Arup kumar kundu et al showed that mortality 
was high in poisoning with monocrotophos and dimethoate (31%) and nil with 
Malathion. In the Mangalore study methyl parathion was the most common 
poison consumed. Karalliedde L, Senanayake N. reported Dimethoate, 
Methamidophos, Malathion, Monocrotophos and fenthion as the common type 
OPC consumed in Srilanka. In the Kashmir valley Phosphomidan (55%), 
Malathion (12%) and Dichlorvas (8.5%) were the commonly used OPC 
compounds for ingestion. In study from Tamilnadu, S.Shivakumar Kumar and 
K.Raghavan et al of Tamilnadu reported Methyl parathion as the most common 
form of exposure in their study group. 
In this case series the severity of poison was directly proportional to 
quantity consumed. The study from West Bengal showed there was a 
correlation between the quantity consumed and the mortality.  
CLINICAL CONTRIBUTES  
 In this case series 93.1 per cent of the cases have the accessibility to 
have their first aid, first doses of atropine and 2PAM within 2 hours. But these 
variables did not have significant correlation with the outcome. But the West 
Bengal workers reported increased mortality among the patients who had 
increased time interval before initial atropinisation (48).    Murat Sungurb et al in 
Turkey reported that the CNS symptoms such as depressed mental status, 
confusion and muscle weakness were the common presentation.  Kenneth 
D.Ketz et.al. from Pittsburg reported neuro psychiatric manifestations, 
ototoxity,    Guillain-Barré (49) –like syndrome and isolated bilateral recurrent 
laryngeal nerve palsy in OPC poisoning.  
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CLINICAL SEVERITY (MODIFIED DREISHBACH CRITERIA)  
 In this case series, all the patients admitted  fell into the  grade 3 group 
of  clinical severity (n=29) 100%. The reason could be that this centre being a 
referral unit, complicated cases, warranting specialist treatment, intensive care 
monitoring, ventilatory support were transferred from primary health centres, 
district hospitals and private nursing homes.  Arup Kumar Kundu (et.al) 
reported, mild 15 (14%), moderate 55 (50.9%), and severe 32 (29.6%) in his 
study based on OPC poisoning in sub-urban West Bengal.   In that study, the 
severe grade of poisoning was associated with   increased ventilatory support 
and poor outcome. Similarly, in this case series, clinical severity association 
with need of ventilatory support and mortality was statistically significant. 
LAB CONTRIBUTES  
        In this study group, the average total WBC count 8,686 cells cubic mm. 
(SD. 3433). Leukocytosis was also reported in the studies from Turkey and 
Pittsburg. The liver function tests observed in this study had similar pattern of 
mild elevation when compared to the study from Murat Sungurb et al in 
TURKEY. Kenneth D. Ketz, et.al. who documented metabolic acidosis in his 
study group.  
CHOLINESTERASE LEVELS AND ITS SIGNIFICANCE  
        In this case study, day 1 ChE correlated very well with clinical criteria of 
Dreisbach. This finding was also observed by Bobba R, Venkataraman,   BV, 
Pais P, Joseph T. et.al. in Bangalore (51). In contrary to this observation,  S.N. 
Chugh and Navneeth Agarwal, et.al. found no relationship between serum CHE 
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estimation and severity grading (52). Sequential post exposure estimations of the 
ChEs up to 3 days revealed significant rise in the values correlated with 
substantial clinical improvement. This observation was in par with the study in 
Bangalore (51).   
SERUM AMYLASE 
In all 29 patients serum amylase and ultra sonogram of the abdomen was 
performed in order to identify transient pancreatitis which is a rare 
complication (53). Ultra sonography of the abdomen was done in all the cases.  
All cases in our series had serum amylase levels of less than 200.  Sahin I,  
Onbasi K,  Sahin H, Karakaya C, Ustun Y, Noyan T. et.al. observed 4 out of  
47 cases  in their  series, had amylase  elevation more than 300 U/L.(54). Lee 
WC, Yang CC, Deng JF, Wu ML, Ger J, Lin HC, Chang FY, Lee SD, et.al. 
stated that, hyperamylasemia was frequent in severe organophosphate 
poisoning. However, hyperamylasemia was not synonymous with acute 
pancreatitis and pancreatic amylase was not a reliable parameter in the 
diagnosis of organophosphate-induced pancreatitis due to its low sensitivity 
and specificity (55).   
TREATMENT CONTRIBUTES 
 In this series, all patients were administered atropine according to the 
clinical severity.  
In this series, 2PAM was given to all patients. 2PAM was administered 
at a dose of 500 mg/hr infusion for the first 48 hrs followed by 1 g IV tds for 
another 3 days. Arun Kumar Kundu, et.al. in a study in sub-urban  West Bengal 
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related high dose  2PAM administered in first 24 hours  was  associated with  
adverse outcome (48). In 1991, De Silva studied the treatment of 
organophosphate poisoning with atropine and 2-PAM and, later the same year, 
with atropine alone. He found that atropine seemed to be as effective as 
atropine plus 2-PAM in the treatment of acute organophosphate poisoning. The 
controversy continued when other authors observed more respiratory 
complications and higher mortality rates with use of high-dose 2-PAM.  
Studies are underway to assess the role of low-dose 2-PAM (42) S.Shivakumar 
and K. Raghavan, et.al. compared the effectiveness of  high dose 2PAM with  
low dose by selection of patients in non-random  manner.  They  found  out  the 
high dose  2PAM group had better  survival, lesser incidence of type 2 
paralysis and shortened  duration of  ventilation.  
VENTILATORY SUPPORT 
Out of 29 patients 21 needed ventilatory support. (72.4%).All patients 
were initiated on assist control mode. 5 out of 21 cases on mechanical 
ventilation expired. The morality rate among patients on mechanical ventilation 
was 23.8%.   
The average duration of mechanical ventilation in the series was 9.2 
days (SD = 6.56).  Grade 3 clinical severity, proximal muscle affection, 
elevation of creatinine Kinase and low values of day 1 serum ChE were the 
predictors for the need of mechanical ventilation.  Murat Sungur and 
Muhammed Güven of Turkey in the study of 47 patients of OPC reported 
mechanical ventilatory support was needed for 10 (21.2%) patients. The 
duration of mechanical ventilation was 4.1 ± 3.2 days. The mortality rate for 
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the patients who were mechanically ventilated was 50% (5 patients), although 
the mortality rate was 27.6% (13 patients) for all patients. The mortality rate 
for the mechanically ventilated patients was not statistically different compared 
with those patients not mechanically ventilated. Two patients who are 
mechanically ventilated died with sudden cardio respiratory arrest following 
ventricular tachycardia, and three died from pneumonia and complicating adult 
respiratory distress syndrome S.Shivakumar and K. Raghavan, et.al. in their  
case  series of 165 patients 22 to patients were mechanical ventilated, out of 
which 14 died.  
NERVE CONDUCTION STUDIES 
All patients underwent nerve conduction studies in the third or fourth 
week of hospital stay according to the clinical severity. In the nerve conduction 
study, compound muscle action potential, sensory nerve action potential and 
nerve conduction velocities were measured in all four limbs. The normal values 
of these parameters were taken as controls.  Thirteen patients had evidence of 
OPIDP. Three patients had evidence of significant axonopathy, 6 patients had 
evidence of demyelination and 8 patients had evidence of sensory neuropathy. 
One patient had evidence of axonopathy, demyelination and sensory 
neuropathy and two patients had evidence of axonopathy and sensory 
neuropathy. One patient had evidence of demyelination and sensory 
neuropathy. Five patients had evidence of demyelination alone and four 
patients had evidence of sensory neuropathy alone. All Patients with 
axonopathy also had evidence of either demyelination or sensory neuropathy or 
both.  
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One patient developed axonopathy, demyelination and sensory 
neuropathy after ingesting 200 ml Dimethoate. Of the patients who had 
axonopathy and sensory neuropathy, one had ingested 100 ml dimethoate and 
the other had ingested 100 ml monocrotophos.  
OUTCOME ANALYSIS  
In this series 5 expired. The mortality rate was 17.2%. In all cases 
primary cause of death was respiratory failure with secondary cardiac arrest. It 
has resulted from central respiratory depression, respiratory muscle weakness, 
increased bronchial secretions, broncho spasm and acute pulmonary oedema. 
The prolonged duration of hospital stay, grade 3 clinical severities, proximal 
muscle involvement and mechanical ventilation were associated with poor 
outcome.  Karalliedde L, Senanayake N. et.al. reported  mortality rate of  18% 
in their study of 92 cases of OPC in Sri Lanka.  Arup Kumar Kundu, JD 
Mukhopadhyay, AK Saha, S Das Burdwan Medical College and Hospital, 
Burdwan, West Bengal analyzed that increased time interval before initial 
atropinisation, higher clinical grading, respiratory paralysis at the time of 
admission, higher quantity of poison consumed, type of poison (e.g., 
monocrotophos and dimethoate), poison ingested rather than inhaled, 
development of encephalopathy and/or is ECG changes (pulse rate < 45/min, 
complete heart block QT-prolongation), and higher dosage of PAM used in 
first 24 hours were  associated with  increased  mortality.  In Kashmir valley a 
study of 164 patients of OPC poisoning, the mortality rate was 5.5%.  In the 
Mangalore study, the mortality was 26.2%. Murat Sungur and Muhammed 
Güven of Turkey reported the mortality rate of 32%.  
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CONCLUSIONS 
¾ Organophosphorous poisoning is most prevalent in the 21-30 age group. 
Incidence is more common in males. 
¾ Organophosphorous poisoning is more common among agricultural 
labourers and unskilled workers. 
¾ The most important cause for consumption of organophosphorous 
poison is self harm. 
¾ The common route of exposure is ingestion of poison and it is associated 
with clinical severity. 
¾ The quantity consumed has direct proportional relationship with severity 
of  poisoning 
¾ The duration of stay in the hospital has significant correlation with 
clinical severity 
¾ The higher the  clinical grade of poisoning at initial presentation more 
the need of ventilatory support and adverse the outcome 
¾ The following parameters predict the need of ventilatory support, grade 
3 clinical severity, proximal muscle affection, low values of day 1 serum 
cholinesterase.  
¾ Ingestion of OPCs produced abnormalities in Nerve Conduction Studies 
in the form of axonopathy, sensory neuropathy and demyelination 
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¾ Ingestion of Monocrotophos produced death in three patients and 
neuropathy in remaining patients. 
¾  Ingestion of Dimethoate produced all the three abnormalities in NCS  
¾ Ingestion of Monocrotophos caused axonopathy and sensory neuropathy 
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AREAS OF FUTURE RESEARCH 
3. Nerve conduction studies may be done on day 1, 3rd week and 6th 
month in order to rule out any pre existing polyneuropathy, to 
identify OPIDP and study its course, respectively. 
4. Repetitive nerve stimulation studies may be done daily for the 
first week to identify intermediate syndrome early 
5. Electromyography may be done. 
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RECOMMENDATIONS 
 As there is no effective treatment for OPIDP, the only way of prevention 
is avoiding the exposure to OPCs. 
 To avoid accidental exposure while spraying pesticides, proper 
precautions should be taken to prevent inhalation and accidental ingestion of 
the substance.  
 Insecticides should be kept out of reach of children, to prevent 
accidental poisoning. 
 Improved regulation of the availability of pesticides, strict regulation of 
vendors, and modifications in packaging of pesticides may all help reduce the 
use of organophosphates as poisons.  
 Adequate provision of information to the public creates awareness about 
the deleterious effects of OPCs.  
 Establishment of poison information centers will facilitate in reducing 
the morbidity and mortality related to organophosphorous poisoning.  
 Many countries like USA, European Union, Thailand banned the 
production and sales of highly toxic OPCs like Monocrotophos. In Srilanka 
severe restrictions are enforced over the utilization of Monocrotophos. So the 
government of India should take necessary steps to restrict the free availability 
of highly toxic OPCs like monocrotophos. 
 60
SUMMARY 
Organophosphorous poisoning is a menace to the human race   both as a 
weapon of mass destruction and a misused pesticide of self harm. The case 
fatality rate exceeds 60% in developing countries where there are many pit falls 
in treatment protocol and research activities. So a comprehensive analysis of 29 
patients of organophosphorous poisoning was done in Poison Centre, 
Government General hospital Chennai. 
All the cases included in the studied underwent detailed clinical 
evaluation, extensive laboratory work up and nerve conduction studies. Each 
patient was monitored periodically till the outcome.  There were 24 males and 
5 female patients. The predominant age group was 21- 30years. 28 patients 
were suicide attempts and 1 had accidental exposure. 27 of the patients were 
poisoned through the gastrointestinal route. One patient had inhalational 
poisoning and one patient had topical exposure. There were 9 different types of 
OP insecticide agents involved. According to Dreisbach clinical criteria at 
admission, all patients belong to the severe grade of poisoning. Serum 
cholinesterase levels had significant correlation with clinical severity, 
mechanical ventilation and outcome.     
Nerve conduction studies were done on the third or fourth week of 
hospital stay. Both upper and lower limb nerves were studied.  Thirteen 
patients had evidence of OPIDP. Three patients had evidence of significant 
axonopathy, 6 patients had evidence of demyelination and 8 patients had 
evidence of sensory neuropathy.  
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PROFORMA 
ANALYSIS OF ORGANOPHOSPHOROUS POISONING 
 NAME : 
 
AGE  : 
 
SEX  :       
 
 OCCUPATION: 
 
ADDRESS:  
 
CONTACT NO:                        
 
 D.O.A                         D.O.D            
 
           DURATION OF STAY:  
 
           OUTCOME: 
 
HISTORY 
 
Type of poison 
 
           Route of exposure    
 
  Ingestional    
  
Topical   
 
 Inhalational 
 
Quantity 
 
Time of onset of poisoning 
 
Time of initiation of first aid (lavage activated charcoal) 
 
 
Time of initiation of atropine 
 
Time of initiation of P2AM 
 
Time taken to reach hospital 
 
Associated poisoning 
 
Associated alcohol intake 
 
           Symptomatology  
 
 Nausea, vomiting in case of ingestion  
Cough, burning sensation in the chest in case of inhalation  
Mild systemic symptoms like headache, dizziness, weakness  
  Abdominal pain, diarrhea in case of ingestion. 
Tightness in chest, difficulty in breathing in case of inhalation 
Salivation,  Lacrimation,   Sweating,  
Pupillary changes.   
Bradycardia,  
Confusion, Tremor, Restlessness. 
    Respiratory depression, generalized weakness  
    Cyanosis, peripheral circulatory failure,  
Convulsions, Coma. 
           Intention of the poison:       
  
Suicidal   
 
Accidental     
 
Homicidal 
 
 
Clinical contributes  
 
Mild           No Symptoms; Normal Vitals, Normal Pupils 
      Moderate Fasciculation; Perspiration, Pupillary changes;  
Tachypnoea; Early pulmonary edema 
Severe Pin point pupil, frank pulm-edema, respiratory 
paralysis,  unconsciousness 
Proximal muscle weakness: 
 
    Bulbar muscle weakness: 
 
    Neck weakness: 
 
 INTERMEDIATE SYNDROME 
 
 Associated Clinical Findings: 
 
 LAB CONTRIBUTES 
 
Hemogram:  
            
            HB              TC                DC               ESR              PCV          
 
 RFT    
                      Urea             Creatinine     Na+       k+      hco3      Cl-  
 
            SUGAR           : 
 
 
CXR:      
 
USG Abdomen: 
 
 ECG:  
 
           Gastric aspirate                                       
 
           Serum pseudo cholineestrase levels 
       DAY1 
       DAY2 
       DAY3 
 LFT:   
 
    SGPT         SGOT          SAP        TB                       
  
          Amylase:     
  
TREATMENT CONTRIBUTES 
 
Antidote 
 
Ventilatory support 
 
Duration 
 
Tracheostomy 
 
Outcome 
 
Other supportives 
                    
                   Blood products 
 
                   Inotropes 
 
                   Dialysis 
 
Nerve conduction studies 
 
                    CMAP 
 
                    MNCV 
 
                    F min 
 
                    SNAP 
 
 
 
